PARP1 and cancer: Pioneering studies in 2005 revealed that concurrent loss of both PARP1 activity and BRCA1/2-mediated homologous recombination (HR) resulted in catastrophic DNA damage and selective tumor cell death, which have fundamentally reshaped strategies for targeted cancer therapies.